他汀对非酒精性脂肪性肝炎肝硬化患者肝细胞癌的化学预防作用
这项回顾性研究纳入1072例NASH相关晚期肝纤维化患者(F3 122例,肝硬化950例),评估肝细胞癌年发病率及他汀的化学预防作用。肝硬化患者HCC年发病率为1.90/100人年(95%CI 1.53-2.35),他汀使用与HCC风险降低相关(HR 0.40,95%CI 0.24-0.67,P=0.001),且呈剂量依赖性。
要点
- NASH相关F3纤维化患者HCC风险低,随访期间未观察到HCC。
- NASH肝硬化患者HCC年发病率为1.90/100人年(95%CI 1.53-2.35)。
- 他汀使用与肝硬化患者HCC风险降低独立相关,且呈剂量依赖性。
核心结论
- NASH相关桥接纤维化患者HCC风险低,而他汀使用可剂量依赖性降低NASH肝硬化患者HCC风险。
研究设计与样本
- 美国2家三级学术中心开展的回溯性研究,纳入2002年7月至2016年6月随访的NASH相关晚期肝纤维化患者1072例(F3 122例,肝硬化950例)。
- 随访从诊断日期至末次腹部影像、肝移植或HCC诊断,采用多因素Cox回归分析按纤维化分期评估HCC危险因素。
主要发现
- F3纤维化患者随访602人年期间未观察到HCC。
- 肝硬化患者中82例发生HCC,年发病率为1.90/100人年(95%CI 1.53-2.35)。
- 肝硬化患者HCC发生与男性(HR 4.06,95%CI 2.54-6.51,P<0.001)、年龄较大(HR 1.05,95%CI 1.03-1.08,P<0.001)和CTP评分(HR 1.38,95%CI 1.18-1.60,P<0.001)相关。
- 他汀使用与HCC风险降低相关(HR 0.40,95%CI 0.24-0.67,P=0.001);他汀累积限定日剂量每增加365,HCC风险降低23.6%。
临床怎么用
- 对于NASH肝硬化患者,他汀使用可能作为HCC化学预防策略,且风险降低呈剂量依赖性。
- NASH相关桥接纤维化患者HCC风险低,但仍需按指南进行监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To estimate the annual incidence of hepatocellular carcinoma (HCC) in patients with nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis, to determine the risk factors for the development of HCC, and to evaluate the chemoprotective effect of statin use stratified by fibrosis stage. METHODS: We conducted a retrospective study at 2 US tertiary academic centers, including patients with NASH-related advanced liver fibrosis (bridging fibrosis [F3] and cirrhosis [F4]) followed between July 2002 and June 2016. Patients were followed from the date of diagnosis to the time of last abdominal imaging, liver transplantation, or HCC diagnosis. Multivariable Cox regression analysis was performed to evaluate the risk factors associated with HCC development, stratified by fibrosis stage. RESULTS: A total of 1,072 patients were included: 122 patients with F3 fibrosis and 950 patients with cirrhosis. No HCC was observed during 602 person-year follow-up among F3 patients. Among patients with cirrhosis, HCC developed in 82 patients with the annual incidence rate of 1.90 per 100 person-years (95% confidence interval [CI], 1.53-2.35). Multivariable analysis in patients with cirrhosis demonstrated that HCC development was associated with male sex (hazard ratio [HR] 4.06, 95% CI, 2.54-6.51, P < 0.001), older age (HR, 1.05, 95% CI, 1.03-1.08, P < 0.001), and CTP score (HR, 1.38, 95% CI, 1.18-1.60, P < 0.001). Statin use was associated with a lower risk of developing HCC (HR, 0.40, 95% CI, 0.24-0.67, P = 0.001). Each 365 increment in cumulative defined daily dose of statin use reduced HCC risk by 23.6%. DISCUSSION: Our findings suggest that patients with NASH and bridging fibrosis have a low risk of HCC. Dose-dependent statin use reduced HCC risk significantly in patients with NASH cirrhosis.
引用
- Pinyopornpanish K, Al-Yaman W, Butler RS, et al. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol. 2021. PMID: 34212895. doi:10.14309/ajg.0000000000001347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。